Stockreport

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver Hig...

Vir Biotechnology, Inc.  (VIR) 
PDF Combination well-tolerated: No grade 3 or higher treatment-related adverse events and no treatment-related discontinuations ECLIPSE registrational program evaluating [Read more]